Biogen to acquire Apellis Pharmaceuticals for $5.6 billion

Biogen will acquire Apellis for approximately $5.6B ($41/share cash) plus up to $4/share in contingent value rights, implying a 140% premium to Apellis’ Mar 30, 2026 close (163% if milestones are met). Apellis’ two C3-targeted drugs, EMPAVELI and SYFOVRE, generated $689M in 2025 and are expected to grow in the mid-to-high teens through at least 2028, supporting the valuation; Apellis represented 1.48% of Worldwide Healthcare Trust’s NAV and the deal was reflected in the trust’s NAV as of Tuesday close.

Analysis

This is a classic strategic tuck‑in where the buyer gains commercial optionality more than pure R&D upside — the second‑order benefit is consolidation of a C3 franchise into a large commercialization engine that can materially accelerate uptake in ophthalmology and rare nephrology markets where real‑world adoption and payer contracting matter as much as label. Expect incremental margin capture through salesforce redeployment and formulary negotiations to show up in BIIB’s operating leverage within 6–18 months, not instantly; those moves also increase demand on biologics CDMO capacity for Apellis SKUs, tightening supplier pricing power for a subset of capacity.

Competitive knock‑on: owners of C5‑centric platforms (the legacy Alexion portfolio inside AZN) face renewed pricing pressure as payers evaluate class economics between upstream C3 vs downstream C5 blockade — a decision that can shift millions in annualized spend per top ophthalmology account. Smaller GA and complement pathway developers without approved products are most vulnerable to rerating; investors should expect accelerated M&A interest across mid‑cap ophthalmology names over the next 12 months as buyers chase similar bolt‑ons.

Key risks and timing: deal integration/execution risk is the dominant downside — mispriced commercial assumptions or supply failures could depress realized synergies and trigger milestone shortfalls over 12–36 months. Payer pushback or unexpected competitive data (e.g., new gene therapy results or head‑to‑head C3/C5 differentiation) are plausible black swans that could erode the premium valuation quickly; regulatory clearance of the deal itself is low probability to fail but monitoring is warranted over the next 3 months.

Contrarian read: the market’s positive knee‑jerk reaction likely underestimates the short‑term margin dip and stock financing/OPCF footprint on Biogen if they lever up for more M&A — upside is real but concentrated in effective launch execution and milestone capture, both binary events that concentrate risk into the 12–24 month window.

Key Decisions for Investors

• Long BIIB equity (6–12 month horizon) sized 1.5–2% of portfolio — add on initial weakness; hedge with a 6–9 month protective put (set strike ~12–15% OTM) or buy a call spread to cap cost. Risk/reward: target 25–35% upside if Apellis sales ramp and synergies materialize; downside capped to ~12–15% with hedges.
• Relative pair: long BIIB / short AZN (or Alexion exposure) for 6–12 months, 1:1 notional — trade seeks 10–20% relative outperformance as C3 commercialization accelerates vs C5 incumbents under payer scrutiny. Use stop if pair underperforms by 8% to limit execution risk.
• Event/volatility play: buy BIIB 9–12 month call spread (buy ATM call, sell 25–30% OTM call) funded by the short leg to target 3:1+ upside/skew if market re‑rates on integration updates; keep position size small (0.5–1% NAV) because catalyst is binary (milestone attainment/commercial execution).
• Defensive short: reduce exposure or consider small short positions in select small‑cap GA/complement developers without approved products (size 0.25–0.5% NAV each) — these names risk being repriced or acquired at lower premiums. Monitor clinical readouts and buyout rumors; mark-to-market aggressively on any positive data.